Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

332.36 -3.83 (-1.14%)

Streaming Delayed Price Updated: 11:00 AM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Today 10:00 EST

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

Via Investor Brand Network

Topics Intellectual Property

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

February 12, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

From BioMedWire

Via GlobeNewswire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

January 29, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

January 11, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

December 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

December 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Announces Changes to Board of Directors

December 03, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

November 08, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 04, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

October 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

October 16, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

October 01, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

September 29, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

September 09, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

September 08, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

August 31, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

August 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

August 27, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

August 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

August 05, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

July 31, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

July 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

June 18, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025

From Instil Bio

Via GlobeNewswire

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

June 09, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Issues 2024 Corporate Responsibility Report

May 20, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.